European Journal of Biomedical and Pharmaceutical Sciences

A COMMUNITY BASED STUDY ON PREVALENCE AND POST VACCINATION EFFECTS OF COVID-19

Bheema Sai Suyagna*, Muvvala Sudhakar, Rajaputana Lakshmi Manisha, Madda Pratibha, B. Lavanya Goud, M. Manikanta Reddy and Ayesha Zoha

ABSTRACT

Background: Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome corona virus 2(SARS-CoV-2), is a global pandemic. There are several factors that are associated with increased prevalence of COVID-19 such as Age, Gender, Comorbid Conditions, Social History. The symptoms of COVID-19 can be classified as MILD (sore throat, headache, aches and pains, diarrhea, rash on skin or discoloration of fingers or toes, Red or irritated eyes), MODERATE (fever, cough, tiredness, loss of taste or smell, sore throat), SEVERE (difficulty breathing or shortness of breath, loss of speech or mobility, confusion, chest pain). Aim and Objectives: To assess the prevalence of COVID-19 among different populations with comorbidities and to assess the post vaccination effects of COVID-19 by estimating the percentage of population suffered from covid in a community, to estimate the reoccurrence and to assess the post vaccination symptoms. Methodology: A prospective observational study was performed in and around Hyderabad as a community based survey with a sample size of 150 subjects who were selected based on inclusion and exclusion criteria. Data was collected.The results were analysed using simple mean and percentage method. Results and Discussion: Out of all 150 subjects, there was equal incidence in both males and females i.e., 50%, about 48% were in the age group 41-76. The percentage of subjects with smoking as a social habit is 20.7%, alcohol consumption is 36% and tobacco consumption is 4%. Comparing the co morbidity in Covid -19 patients, hypertension was the highest found comorbidity with a percentage of 28% and least was asthma with 2.6%. The most commonly found symptoms were A, B (headache, cough, fatigue, loss of smell, sore throat, loss of taste, breathing difficulty, fever, shortness of breath) with a percentage of 91.3% and the least observed symptoms were B (loss of taste, breathing difficulty, fever, shortness of breath). 61.3% of subjects have mild severity, 32.7% with moderate severity followed by 6.0 with major severity. Around 17% of subjects were affected with covid during the 1st wave, 67% were affected during the 2nd wave, while 16% were affected during the 3rd wave. Around 17% of subjects were affected with covid during the 1st wave, 67% were affected during the 2nd wave, while 16% were affected during the 3rd wave. Around 22.6% of subjects were recovered in 14 days, 20% were recovered in 10 days, 16.6% in 7days, 10.6% in15days, 8% in 12days, 4.6% for 5 and 8days, 2.6% for 20 and 6 days. While analysing the reoccurrence, 97% of subjects’ do not have any reoccurrence of covid. Around 91% of subjects were vaccinated with both dose 1 and dose 2, followed by 7% with only dose 1, while 2% were not vaccinated. Around 80% of subjects were vaccinated with covidshield, 18% with covaxin and 2% with Pfizer. While analysing the post-vaccination symptoms, 72% of subjects experienced fever, chills, body pains, joint pains, headache as post vaccination symptoms and 2.7% experienced diarrhoea, nausea, rash, allergy and 24% experienced a combination of the above all symptoms. Conclusion: As enumerated from the current study, COVID-19 infection has been reported from all different age group patients. Severity of infection could be varied from asymptomatic infection to critical disease. Clinical severity of COVID-19 was defined in 5 different groups. They are: asymptomatic, mild, moderate, severe and critical. The post vaccination symptoms experienced were fever, chills, body pains, joint pains.

Keywords: Covid-19, Comorbidities, Symptoms, Post-vaccination effects.